Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegylated interferons.

Umaprasanna S Karnam1, K Rajender Reddy

  • 1Department of Gastroenterology and Hepatology, Central Utah Medical Clinic, 36 North 1100 East, American Fork, UT 84003, USA.

Clinics in Liver Disease
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence Supporting Utility of the Oral Cholate Challenge Test of Liver Function and Physiology to Aid Clinical Management: A Review of Analytical and Clinical Validation Studies.

Gastro hep advances·2026
Same author

Midodrine versus placebo in patients with acute-on-chronic liver failure with ascites-A randomized trial (MIDAS trial).

Hepatology communications·2026
Same author

Frailty Increases Hospitalization Rates in an Ambulatory Cohort of Patients With Cirrhosis: The North American Consortium for the Study of End-Stage Liver Disease 3 Prospective Cohort.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort.

The American journal of gastroenterology·2026
Same author

Delisting for clinical improvement as a proxy for recompensated cirrhosis on the U.S. liver transplant waitlist: A retrospective cohort study.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

Recompensation in Patients With Alcohol-Related Liver Disease-A Multicenter Study.

Gastro hep advances·2026
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Pegylated interferons (IFNs) offer improved pharmacokinetics, enhanced efficacy, and comparable safety versus standard IFNs for chronic Hepatitis C virus (HCV) treatment. Once-weekly dosing of pegylated IFNs improves patient adherence.

Area of Science:

  • Pharmacology
  • Hepatology
  • Virology

Background:

  • Standard interferon (IFN) therapy for chronic Hepatitis C virus (HCV) has limitations.
  • Pegylated interferons (IFNs) represent an advancement in IFN-based therapy.

Purpose of the Study:

  • To compare the pharmacokinetic and clinical profiles of pegylated IFNs with standard IFNs.
  • To evaluate the efficacy and tolerability of pegylated IFNs in treatment-naïve chronic HCV patients.

Main Methods:

  • Pharmacokinetic analysis comparing pegylated IFNs and standard IFN.
  • Clinical trial data assessing efficacy and adverse events.
  • Evaluation of patient adherence based on administration frequency.

Main Results:

Related Experiment Videos

  • Pegylated IFNs exhibit longer half-life, reduced immunogenicity, and improved pharmacokinetics.
  • Enhanced biological activity and greater efficacy observed with pegylated IFNs.
  • Comparable adverse event profiles and improved adherence with once-weekly pegylated IFN administration.

Conclusions:

  • Pegylated IFNs demonstrate superior pharmacokinetic properties and enhanced efficacy compared to standard IFN.
  • Pegylated IFNs, in combination with ribavirin, are the established standard of care for treatment-naïve chronic HCV patients.
  • The improved profile of pegylated IFNs translates to better treatment outcomes with similar tolerability.